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Abstract 
Telomerase activity has been regarded as a critical step in cellular 
immortalization and carcinogenesis and because of this, regulation of 
telomerase represents an attractive target for anti-tumour specific 
therapeutics. Recently, one avenue of cancer research focuses on antisense 
strategy to target the oncogenes or cancer driver genes, in a sequence 
specific fashion to down-regulate the expression of the target gene. The 
protein catalytic sub-unit, human telomerase reverse transcriptase (hTERT) 
and the template RNA component (hTERC) are essential for telomerase 
function, thus theoretically, inhibition of telomerase activity can be achieved 
by interfering with either the gene expression of hTERT or the hTERC of 
the telomerase enzymatic complex. 
The present study showed that phosphorothioate antisense oligonucleotide 
(sASO)-nuclear localization signal (NLS) peptide conjugates targeting 
hTERC could inhibit telomerase activity very efficiently at 5 M 
concentration but less efficiently at 1 M concentration. On the other hand, 
siRNA targeting hTERT mRNA could strongly suppress hTERT expression 
at 200 nM concentration. It was also revealed that siRNA targeting hTERT 
could induce telomere attrition and then irreversible arrest of proliferation 
of cancer cells.  
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Introduction 
Human telomere is a nucleotide sequence about 10-15 kbp long at birth composed of 
the approximately 2500 times repeated sequence of the G rich hexanucleotide 5’-
TTAGGG-3’ at the end of each chromosome protecting chromosomes from fusion with 
another chromosome and from being recognized as damaged DNA by DNA repair system 
[1]. The 3’-terminal end of this sequence is a protruding single-stranded 150–200 
nucleotides long extension. The 10-15 kbp telomere forms a large ring structure called 
telomeric loop (T-loop). The 150 – 200 nucleotides 3’-overhanging single stranded 
terminal end invades the 5’-double stranded telomeric duplex forming a triple stranded 
D-loop that is distinct from a DNA break thus protecting it from the DNA damage repair 
machinery[2]. The structure of the telomere is stabilized by the association of the telomeric 
DNA with six proteins that form the shelterin complex[3]. These proteins include the 
Protection of Telomeres 1 (POT1) which binds to the single stranded region of the D-
loop the Telomere Repeat Binding Factor (TRF2) which binds to the double stranded 
region of the D-loop and the Telomere Repeat Binding Factor 1 (TRF1) which binds to 
the double stranded region of the T-loop[4]. Binding of the shelterin complex to the 
telomeric DNA prevents stimulation of the DNA damage response, chromosome fusion 
and degradation of genes near the end of the chromosomes[5].  
The telomere’s length decreases with age, getting shorter by 50-200bp after each 
replication, eventually reaching a minimal length at which the end of the chromosomes 
is no longer protected[6]. Telomere attrition activates DNA damage response and induces 
cellular senescence, apoptosis and/or a permanent cell cycle arrest in G1 phase due to 
inhibition of cyclin dependent kinases (CDKs) by the p53/p21 or p16/Rb pathways 
(cellular senescence)[7].  
Cellular senescence is considered as one of the safeguard mechanisms against 
carcinogenesis.  However, it can also promote carcinogenesis by the secretion of an array 
of diverse cytokines, chemokines, growth factors, and proteases known as the senescence-
associated secretory phenotype (SASP). It is pointed out that SASP can be a key factor 
correlating the molecular to chronological age and implies that clearance of senescent 
cells could alleviate age-associated pathologies[8]. 
It has been reported that telomere shortening can be found in fibroblasts derived from 
hypodermis, melanocytes, spleen, B cells, T cells, kidney and liver[9]. There is evidence 
suggesting that telomere is highly susceptible to oxidative stress-mediated DNA damage 
and telomere length is associated with high level of psychological stress, smoking, obesity 
and low social status[10]. Also accumulating evidence endorses the view that shortened 
telomeres are linked to senescence in genetically modified animals. It has been reported 
for example that deletion of telomerase gene in mice accelerated aging and reduced life 
span suggesting that shortened telomeres may induce progeroid syndromes. The 
telomeres’ length of aged human leucocytes has also been associated with higher risk of 
death by infection[11]. 
Disordered proliferation of cancer cells is induced by activation of oncogenes or 
inactivation of tumour suppressor genes and immortality of cancer cells depends on 
telomere maintenance by telomerase activation. Telomerase activity is hardly detected in 
normal somatic cells but is present at a high level in cancer cells, about 80% in lung 
cancer cells and 95% in esophageal cancer cells. Therefore, telomerase has attracted much 
attention as a suitable target for cancer treatment since inhibition of the telomerase 
activity could result in telomere attrition and consequently interruption of immortality of 
cancer cells[12]. 
Human telomerase is a reverse transcriptase which consists of the catalytic subunit 
(hTERT), the RNA component (hTERC) as a template for reverse transcription, and 
regulatory subunits such as dyskerin and TEP1. The genes encoding for the telomerase 
subunits TERT, TERC, DKC1 and TEP1 are located at different chromosomes. The 
hTERT contains 1132 amino acids and hTERC contains 451 nucleotides. hTERT adds 
single stranded 5’-TTAGGG-3’ repeats to the 3' strand of chromosomes using the TERC 
template region (3’-CAAUCCCAAUC-5’). 
In our previous study, we investigated syntheses and antisense efficiencies on 
telomerase activity of normal phosphodiester antisense oligonucleotides (ASO)-nuclear 
localization signal peptide (NLS) conjugates and phosphorothioate antisense 
oligonucleotides (sASO)-NLS conjugates targeting hTERC and showed that sASO-NLS 
conjugates largely inhibited telomerase activity up to 99.6% in Jurkat cells while ASO-
NLS conjugates inhibited telomerase activity only slightly. It could be interpreted that 
nuclear localization of s-ASO-NLS conjugates efficiently enhanced binding of sASO-
NLS to hTERC [13]. 
In the present study, we investigated inhibition of telomerase by sASO-NLS 
conjugates targeting hTERC and suppression of hTERT gene expression, telomere 
attrition and proliferation arrest of cancer cells by siRNA targeting hTERT mRNA. 
 
Materials and Methods 
Solid Phase Synthesis of Peptide Fragments 
Four peptides listed in Table 1 were prepared by a standard fmoc-chemistry using 100 
mg of Wang resin (novabiochem, 100-200 mesh, 0.50-1.30 mmol/g). The peptide 1a is 
derived from a nuclear localization signal (NLS) sequence of SV-40 large T antigen [14], 
1b is derived from NLS of HIV-1 tat protein [15], 1c is derived from nuclear export signal 
(NES) peptide of HIV-1 rev protein [16] and 1d is a designed amphiphilic peptide which 
was proven to act like an NES signal in our previous study [13]. -Amino groups of lysine 
underlined (K) next to the C-terminal glycine (G) were initially protected by tert-
butyloxycarbonyl (boc) group and finally deprotected after the treatment with TFA 
resulting in setting the amino groups reactive in further conjugation reactions. On the 
other hand, -Amino groups of lysine (K) were protected with trifluoroacetyl (tfa) groups 
even after the treatment with TFA resulting in keeping the amino groups unreactive in 
further conjugation reactions and were deprotected by the treatment with NH4OH at the 
final stage of SPFC.  The obtained peptides were fully characterized by RP-HPLC and 
MALDI-TOF-MS to give satisfactory results. 
 
Synthesis of Phosphorothioate Oligonucleotide-Peptide Conjugates by SPFC  
The synthesis of ASO-peptide conjugates involved a solid phase fragment 
condensation (SPFC) as shown in Scheme 1. Using the commercially available 
phosphoramidite (Glen Research 5’-Amino Modifier5) a phosphorothioate 
oligonucleotide assembled in 1 mol scale on CPG (PROLIGO, 500 Å, 30-40 mol/g) 
support was modified at the 5’-end of the oligonucleotides [17]. Next a bifunctional linker 
molecule, carbonyldiimidazole (CDI) [18], was reacted with the terminal amino group on 
solid phase, and then partially protected peptide fragment [19] bearing a single free reactive 
amino group, independently synthesized and purified, was reacted with the CPG-linked 
phosphorothioate oligonucleotide [20] to give phosphorothioate oligonucleotide-peptide 
conjugates still attached to CPG [21]. In the peptide fragments, trifluoroacetyl (tfa) group 
protected the -amino groups of lysine (K) except for a reactive site, thiols of cysteine 
(C) and hydroxyls of serine (S) and threonine (T) are protected by acetyl (ac) group, and 
guanidyl and carboxyl group are already deprotected before the condensation. Finally, 
CPG-linked products are treated with concentrated aqueous ammonia at 55°C for 4 h to 
give fully deprotected product. Reversed phase HPLC purification gives a single peak 
pure product in 3-13% over-all yields in >95% purities and all the products are fully 
characterized by MALDI-TOF-MS to give satisfactory results (Table 2). The 
phosphorothioate oligonucleotide-peptide conjugate was transfected to Jurkat cells and 
later evaluated the effect on telomerase activity by TRAP assay. 
 
Cell Culture 
Adherent cells (HeLa) and Suspension cells (K562 and Jurkat) were maintained in 
RPMI 1640 medium containing FBS and antibiotic and incubated at 37oC, 5% CO2 
atmosphere in a humidified incubator. Cells were regularly cultured to maintain 
exponential growth. 
 
Transfection of sASO-Peptide Conjugates 
Four sASO-peptide conjugates were used in the experiment namely: sASO-SV-
40LT-ant NLS (2a); sASO-HIV-1 tat NLS (2b); sASO-HIV-1 rev NES (2c) and sASO-
(LRAL)4 (2d). Two concentrations of sASO-peptide conjugates (1 M and 5 M) were 
examined and compared. 
Jurkat cells were seeded in 24-well flat-bottomed plates at a density of 2 x 105 
cells/well in a 0.5 ml of growth medium without antibiotic. Then cells were transfected 
once with the conjugates diluted in a serum-free OptiMEM (Invitrogen, Life 
Technologies Corporation, USA). Jurkat cells were then incubated at 37°C humidified 
atmosphere containing 5% CO2. Telomerase activity was examined 24 h and 48 h after 
the end of transfection. 
 
Telomerase Activity Detection Assay 
The TRAPeze® telomerase detection kit (Chemicon International, USA) was used 
according to the manufacturer’s protocol with a minor modification. Briefly, cells were 
harvested and washed once with chilled PBS and then homogenized in 200 l 1 x CHAPS 
lysis buffer on ice for 30 min and centrifuged at 12,000 X g for 20 min at 4oC. The 
supernatant liquid was collected and BCA protein assay kit (Pierce Biotechnology, USA) 
was used to measure protein concentration. Sets of diluted protein aliquots were tested 
for each sample in the TRAP assay to establish the linearity of the assay. Telomerase 
reaction was carried out at 30oC for 30 min followed by a 3-step PCR amplification (94oC, 
30 sec, 59oC, 30 sec and 72oC, 1 min for 33 cycles). The amplified products were 
electrophoresed on a 12.5 % non-denaturing polyacrylamide gel. The gel was stained with 
SYBRⓇ green nucleic acid stain (Molecular Probes, USA) and analysed with Doc-ItLS 
UVP ver.5.5.4 (Life Science Software, USA). Telomerase activity was quantified from 
all assays within the linear range by normalizing the total amount of reaction products 
(telomeric bands) in each lane to the signal obtained from the internal telomerase assay 
standard present in the same lane, as described in the kit’s protocol. TSR8 indicates a 
telomerase quantitation control which serves as a standard for estimating the amount of 
TS primers with telomeric repeats extended by telomerase. In each gel tested, a positive 
control reaction (C+) indicates amplified products in untreated cells and a negative 
control (C-) indicates a 36 bp internal control produced by primer K1 and TSK1 
oligonucleotide contained in the assay kit. Levels of telomerase activity were obtained 
from a minimum of three assays of at least two independent prepared extracts from each 
sample. 
The methodology utilized in the TRAPEZE® Gel-Based Telomerase Detection kit is 
based on an improved version of the original method described by Kim et al [22]. This 
technique is a highly sensitive in vitro assay system utilizing the polymerase chain 
reaction. In the first step of the reaction, telomerase adds a number of telomeric repeats 
(TTAGGG) onto the 3’-end of a substrate oligonucleotide (TS). In the second step, the 
extended products are amplified by PCR using the TS and RP (reverse) primers, 
generating a ladder of products with 6 base increments starting at 50 nucleotides: 50, 56, 
62, 68, etc. This kit reduces amplification artefacts and permits better estimation of 
telomerase processivity. 
 
Selection of the Target Sequence of siRNA 
A total of 6 siRNA sequences targeting different hTERT mRNA sequences were 
evaluated and screened to choose the most effective siRNA sequence that showed the 
highest inhibitory/silencing effect on the hTERT mRNA expression. All siRNAs were 
chemically synthesized, purified and annealed (Qiagen Co. Ltd, Japan) with a two-
nucleotide overhang at the 3’-end. The list of siRNA sequences is shown in Table 3. All 
siRNA sequences were submitted in a BLAST search of human EST libraries 
(http://www.ncbi.nlm.nih.gov/blast/) to confirm that only hTERT gene was targeted. A 
scrambled (non-silencing) siRNA was also purchased from Qiagen (Cat. No. 1022076) 
and used as the negative control. 
 
siRNA Transfection 
Adherent  cells: One day before transfection, HeLa cells were plated in a 24-well 
flat-bottomed plate. Cells were seeded at a density of 1 x 105 cells/well in a 0.5 ml of 
growth medium without antibiotics so that cells will be about 90-95% confluent at the 
time of transfection. 
Suspension  cells: On the day of transfection, K562 and Jurkat cells were 
separately seeded in 24-well flat-bottomed plates at a density of 4 x 105 cells/well in 0.5 
ml of growth medium without antibiotics. 
The cells were transfected with siRNA (200 nM concentration) complexed with 
Lipofectamine® 2000, according to the manufacturer’s instructions (Invitrogen, Life 
Technologies Corporation, USA). Cells were then incubated at 37oC, 5% CO2
 atmosphere 
in a humidified incubator. Cells were harvested and assayed 24 h after transfection.  
Note: The transfected cells were first screened for qRT-PCR to detect the effect of the 
different siRNA sequences in silencing the hTERT mRNA gene expression. The best 
sequence with the highest inhibitory effect to the hTERT mRNA gene expression was 
further evaluated for TRAP assay and Proliferation assay. 
 
Quantitative Reverse Transcriptase –Polymerase Chain Reaction (qRT-PCR) 
hTERT mRNA level was quantified by Real-Time, two-step reverse transcriptase-
PCR (qRT-PCR) method. Briefly, total RNA was extracted using the RNeasy Plus Mini 
Kit (Qiagen). Two-step RT-PCR was carried out using SuperScriptTM III Platinum® 2-
Step qRT-PCR kit (Invitrogen, Life Technologies Corporation, USA) according to the 
manufacturer’s instructions. The conditions of the 2-step RT-PCR were as follows: 2 min 
at 50oC, 2 min at 95oC and then 45 cycles of amplification for 30 sec at 95oC and 1 min 
at 62oC.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal 
control to ensure accuracy. Fluorescence was measured in real time using the MX3005P®, 
Stratagene and TaqMan probe and primers shown below. 
Forward primer; 5’-ACGGCGACATGGAGAACAA-3’ 
Reverse primer; 5’-CACTGTCTTCCGCAAGTTCAC-3’ 
TaqMan probe: 5’-FAM d(CTCCTGCGTTTGGTGGATGATTTCTTGTTG)BHQ-1-3’ 
 
Cell Proliferation Assay 
Cellular proliferation was assayed using Cell Proliferation Reagent WST-1 (4-[3-(4-
Iodophenyl)-2(4-nitrophenyl)2H-5 tetrazolio]-1,3-benzene disulfonate (Roche Applied 
Science and Diagnostics, Germany). It is a colorimetric assay system for the 
quantification of cell proliferation and cell viability based on the cleavage of the 
tetrazolium salt WST-1 by mitochondrial dehydrogenase in viable cells. In brief, 1 x 104 
cells/well were incubated in a 96-well plate, in the presence or absence of siRNA, at 37oC, 
5% CO2 atmosphere in a humidified incubator. About 10 l of WST-1 reagent was added 
to each well. After 4 hours, absorption at 450 nm was determined on a Wallac 1420 
ARVOmx/Light spectrophotometer reader (Perkin Elmer, USA). The proliferation 
inhibition rate was calculated as follows: Inhibitory rate = (Abs control – Abs sample) / 
(Abs control – Abs blank) X 100, where Abs control is the absorbance value of cells 
without treatment, Abs sample is the absorbance value of cells treated with antisense 
agent, Abs blank is the absorbance value of media (RPMI) as blank control. 
 
Results and Discussions 
As described above, we investigated syntheses and antisense effects of 6 types of 
normal phosphodiester ASO-peptide conjugates and one type of sASO-NLS conjugate 
and revealed that only the sASO-NLS conjugate showed an excellent antisense inhibition 
of telomerase activity while normal phosphodiester ASO-NLS conjugates showed almost 
no effects[13]. Therefore, first we focused on syntheses and evaluation of antisense effects 
of sASO-peptide conjugates targeting hTERC in this study.  
 
Synthesis of sASO-Peptide Conjugate 
Solid phase fragment coupling of peptides with oligonucleotide involves the synthesis 
of the oligonucleotide and peptides on separate solid support and later be reacted and 
linked with each other[13].  Table 1 shows the synthesized peptides with the corresponding 
percentage yield and the correct mass as found in MALDI-TOF-MS. The obtained 
peptides have been successfully synthesized and purified using reverse phase HPLC and 
further characterized by MALDI-TOF-MS to give satisfactory results.  
An advantage of the solid phase fragment coupling route is that peptide components 
can be purified by reverse phase HPLC before conjugation, making it easier to identify 
and purify the conjugation products after cleavage from the solid support. As shown in 
Table 2, conjugates were successfully purified by reversed phase HPLC and the correct 
mass is shown. 
 
Inhibition of Telomerase and Telomere Attrition by sASO-Peptide Conjugates 
Targeting hTERC 
Antisense inhibition effects of synthesized sASO-peptide conjugates targeting 
hTERC of were evaluated in Jurkat cells using telomeric repeat amplification protocol 
(TRAP) assay.  
The conjugates were transfected into Jurkat cells without the use of cationic lipid as 
transfecting agent at a concentration of 5 M and 1 M. These concentrations were 
chosen because based on the report of Chen et al[23] 5 M was the concentration that 
produced maximal inhibition of telomerase by anti-hTERC oligonucleotide in their work. 
While several papers reported that the IC50 values for inhibition of telomerase in various 
cell lines were measured to be as low as 0.5 M [24]. Cells were harvested, one batch after 
24 h while another batch after 48 h. 
A representative example of PAGE image of TRAP assay using 5 M sASO-peptide 
conjugate in Jurkat cells is shown in Figure 1A (24 h) and Figure 1B (48 h). The relative 
telomerase activity for each sample is presented as percentage of the telomeric product 
generated (TPG) (average of 3 assays) in Figure 2. Decreased telomerase activity was 
apparent in Jurkat cells treated with 5 M of each of the conjugates as compared to the 
intensity of bands seen in the positive control and the TSR8 standard. However, as shown 
in Figure 2, the sASO-NLS conjugates, 2a and 2b showed a much higher inhibitory effect 
(approximately 96% and 80% respectively) than sASO-NES conjugates 2c and 2d 
(approximately 20% and 50% respectively) after 24 h of transfection as it was evident by 
the reduced number of telomeric ladder pattern. After 48 h the inhibitory effect of the 
conjugates was slightly reduced.  
In Jurkat cells treated with 1 M of each of the 4 conjugates, only a slight reduction 
of telomerase activity was observed. The results of TRAP assay as TPG units are shown 
in Figure 3. Taken together the results shown in Figures 2 and Figure 3 indicate that 
sASO-NLS conjugates repressed telomerase activity very efficiently at 5M in Jurkat 
cells. 
These results clearly indicated the importance of intracellular trafficking of ASOs for 
antisense activities. As demonstrated in our previous studies[13], ASO-NLS conjugates 2a 
and 2b were expected to be recognized by importin  and transported into the cellular 
nucleus, and ASO-NES conjugates 2c and 2d were expected to be recognized by exportin 
and transported out of the nucleus. The target hTERC is located in the cellular nucleus 
and ASO-NLS conjugates 2a and 2b could bind the target hTERC more effectively than 
ASO-NES conjugates 2c and 2d.   
 
Suppression of hTERT mRNA Expression by siRNAs Targeting hTERT 
RNA interference (RNAi) is a sequence specific post transcriptional gene silencing 
process, which is triggered by double stranded RNA (dsRNA), causing degradation of 
mRNAs homologous in sequence to the dsRNA that subsequently leads to effective 
inhibition of the expression of a specific gene[25, 26]. As reported by Santoyo et al[27], the 
effectiveness of the chemically synthesized short double stranded siRNA is likely to be 
determined by the accessibility of its target sequence in the intended substrate. They 
further suggested that there are no reliable ways of predicting or identifying the “ideal” 
sequence for a siRNA and the selection of siRNAs sequences is largely empirical. Site 
selection is one of the confronting challenges in nucleic acid-base gene inactivation 
strategies. Like that of antisense DNA and ribozymes approaches, the use of various 
siRNAs directed at different sites of the target gene exhibit different suppression effect[28].  
First, 6 different 21bp siRNA sequences that target different sites of hTERT mRNA 
were screened (Please refer to Table 3 for the sequences). There were two GenBank 
entries namely NM_198255 and AB085628 for hTERT gene mRNA transcript that were 
considered for the site selection of siRNAs sequences. These two GenBank entries gave 
the complete coding segment of Homo sapiens mRNA for hTERT. The complete coding 
segment is important because it describes the gene’s open reading frame (ORF). The 
siRNAs were designed using bioinformatics algorithm software programs developed by 
Thomas Tuschl and Fran Lewitter of Whitehead Institute 
(http://www.jura.wi.mit.edu/siRNA). The website provided tools to blast-search in 
GenBank the designed siRNA to confirm that only hTERT gene was targeted.  
The siRNA transfection was carefully optimized for both adherent cells (HeLa) and 
suspension cells (K562 and Jurkat). The 6 siRNA sequences were transfected into cells 
using cationic lipid (Lipofectamine® 2000) at a concentration of 200 nM; this was chosen 
because it was the highest concentration that could be used to inhibit telomerase without 
causing most of the cells to die, as reported in the work of Natarajan et al[29]. The 
transfected cells were allowed to grow for 24h. Then, they were harvested for quantitative 
RT-PCR to screen the effective siRNA sequence that efficiently silences the hTERT gene 
expression.  
The quantitative RT-PCR analyses of the hTERT mRNA expression by the 6 siRNAs 
at 200 nM are shown in Figure 4. Since we could initially observe 40% reduction of 
hTERT mRNA in Jurkat cells by siRNA-3, we extended cancer cell lines tested to three 
cell lines, Jurkat, HeLa and K562. Of all the siRNAs tested, only the siRNA-3 appeared 
to reduce hTERT mRNA levels in all 3 cancer cell lines.  An approximately 70% 
reduction of hTERT mRNA was observed in HeLa cells using siRNA-3 and 60% and 
50% in K562 and Jurkat cells respectively. 
Compared to scrambled siRNA as a negative control, the cells treated with siRNA-3 
exhibited different degrees of reduction in the hTERT mRNA expression. The most 
efficient reduction of the hTERT mRNA levels occurred in HeLa cell transfected with 
the siRNA-3 for 24 h compared to those elicited by K562 and Jurkat cells under the same 
conditions. 
It has been reported that strand selection of siRNA in RNA induced silencing complex 
(RISC) is highly correlated with the thermodynamic stability of both 5’-ends of siRNA 
and that siRNA bearing A or U at 5’-end of antisense strand and G or C at 5’-end of sense 
strand shows enhanced RNA silencing effect[30]. Since only siRNA-3 among 6 siRNAs 
designed in the present study has A at 5’-end of antisense strand and G at 5’-end of sense 
strand, the most efficient silencing effect of siRNA-3 might be attributed that the 
antisense strand of siRNA-3 was more preferably selected as a guide strand in RISC than 
that of other siRNAs. 
Threfore, further biological assays carried out in this study such as TRAP and cell 
proliferation assays were performed using the siRNA-3. 
 
Telomere Attrition Induced by siRNA Targeting hTERT 
The effect of the hTERT siRNA on telomerase activity was evaluated by telomeric 
repeat amplification protocol (TRAP) assay. Gel electrophoresis (Figure 5) showed that 
cancer cells transfected with 200 nM siRNA after 24 h exhibited reduced telomerase 
activity compared to the untreated cells as a positive control. A distinct and clear 6 bp 
ladder pattern was observed in the positive control compared to the treated cells. 
Decreased telomerase activity was evident in transfected K562, Jurkat and HeLa cells. 
The ladder pattern of telomerase activity observed after polyacrylamide gel 
electrophoresis (PAGE) was semi-quantitatively analysed employing the Doc-ItLS UVP 
ver.5.5.4 software. The obtained data as total products Generated (TPG) shown in Figure 
6 indicate decreased telomeric repeat banding pattern in the treated cells suggesting 
down-regulation of telomerase activity in these cells. HeLa cells showed the lowest 
number of telomeric repeats compared to K562 and Jurkat treated cancer cell lines. 
Decreased TPG units in the treated cells imply that the telomerase activity was 
affected by the siRNA mediated silencing of the expression of the targeted subunit of the 
telomerase holoenzyme. 
Results of the proliferation assay shown in Figure 7 indicated decreased proliferation 
of the cells treated with 200 nM siRNA-3 targeting hTERT suggesting that hTERT 
inhibition decreased cell proliferation in these cells. Among the 3 cancer cell lines treated 
with siRNA-3, HeLa showed a marked decrease in cell viability.  
It is interesting to note that the qRT-PCR results correlated with the results obtained 
from the TRAP assay. Hahn et al suggested that the expression pattern of hTERT gene is 
rate-limiting determinant of the enzymatic activity of human telomerase[31]. In addition, 
many reports have demonstrated that specific hTERT siRNA could successfully inhibit 
telomerase activity in several cancer cell lines[32, 33]. 
 
Proliferation Arrest Induced by siRNA Targeting hTERT 
Rapid and accurate assessment of viable cell number and cell proliferation is an 
important requirement in many experimental situations involving in vitro and in vivo 
studies. Accurate assessment of cell proliferation is useful especially in the determination 
of the cytostatic potential of anti-cancer compounds. 
Several laboratories have reported that inhibition of hTERT expression causes 
immediate anti-proliferative effect[34-36]. In the present study, the effect of siRNA-3 
targeting hTERT mRNA on cell proliferation was also evaluated. The results of the 
proliferative assay  showed dramatically decreased proliferation in all three cancer cell 
lines treated with 200 nM of siRNA-3 (Figure 7).   
In this study, the quantification of the formazan dye produced by metabolically active 
cells was measured using spectrophotometer at an absorbance wavelength of 450 nm. The 
result of this study is consistent with the report of Kraemer et al indicating that inhibition 
of telomerase activity by targeting hTERT also caused significant inhibition of 
proliferation and induction of apoptosis in cancer cells[35]. They suggested that this rapid 
loss of cell viability could be attributable to the cells bearing very short telomeres or to a 
rapid telomere loss mechanism after telomerase enzyme activity had been down-
regulated. Thus, telomerase inhibitors by themselves can result in telomere shortening. 
It is therefore an important challenge for basic and preclinical work to determine 
combination therapies to enhance telomeres erosion and consequently rapid decrease of 
cancer cell proliferation without affecting normal cell telomeres. 
 
Conclusions 
This study showed that sASO-NLS conjugates efficiently inhibited telomerase 
activity at higher concentration (5 M) and siRNA could strongly suppress hTERT 
mRNA level at much lower concentration (200 nM). It should be also pointed out that 
suppression of hTERT mRNA level by siRNA induced telomere attrition and irreversible 
arrest of proliferation of cancer cells. Recently we reported that siRNA-NES conjugates 
suppressed BCR/ABL gene expression up to 96.0% in human myelogenous leukemia cell 
line K562[37]. Studies on siRNA-NES conjugates targeting hTERT and further 
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Scheme 1. Synthesis of ASO-Peptide Conjugates by SPFC 
 
Figure 1. Inhibition of Telomerase Activity by ASO in Jurkat Cells. 
 [ASO] = 5 M, 6A; 24h, 6B; 48h after transfection. Lane 1; M: 50bp Molecular Weight 
Marker, Lane 2; C+: positive control (untreated cells), Lane 3; TSR8 (quantitation 
standard), Lane 4; ASO-2d Lane 5; ASO-2c, Lane 6; ASO-2b, Lane 7; ASO-2a, Lane 8; C-: 
negative control (internal control). 
 
Figure 2. Telomerase Activities as Telomerase Product Generated (TPG) units in Jurkat 
cells.  [ASO] = 5 M.  Control; the value for amplified products in untreated cells as a 
positive control. The results were expressed as mean ± SD from three determinants. 
 
Figure 3. Telomerase Activities as Telomerase Product Generated (TPG) units in Jurkat 
cells. [ASO] = 1 M. Control; the value for amplified products in untreated cells as a 
positive control. The results were expressed as mean ± SD from three determinants. 
 
Figure 4. Silencing of hTERT by siRNA1-6 in HeLa, Jurkat and K562 Cells. 
Quantified by real time RT-PCR. [siRNA] = 200 nM, 24 h after transfection.  
Control; scrambled (non-silencing) siRNA. The results were expressed as mean ± SD 
from three determinants. 
 
Figure 5. Inhibition of Telomerase Activity by siRNA-3 by TRAP Assay.  
The TRAP assay products were resolved in a 12.5% non-denatured PAGE, stained with 
SYBRⓇ green gel stain. [siRNA-3] = 200 nM. Lane 1; C+: positive control (untreated 
cells). Lane 2; TSR8 (control template as a quantification standard). Lane 3; M: 50bp 
Molecular Weight Marker. Lane 4; K562. Lane 5; Jurkat. Lane 6; HeLa. Lane 7; C-: 
negative control (internal control).  
 
Figure 6. Telomerase Activities as Telomerase Product Generated (TPG) units. 
[siRNA-3] = 200 nM, 24 h after transfection. Control; the value for amplified products 
in untreated cells as a positive control. TSR8; quantitation standard. The results were 
expressed as mean± SD from three determinants. 
 
Figure 7. Inhibition of Proliferation of Cancer Cells by siRNA-3 
Cell Proliferation Reagent WST-1 was used to measure for cell viability after 24h 
transfection of siRNA-3 (200 nM). Control; absorbance value for untreated cells 
(negative control), Blank; absorbance value of media (RPMI). The values were 
normalized based on the values for each negative control. The results were expressed 
as mean ± SD from three determinants. 
 
Table 1. MALDI TOF MS of Synthesized Peptides 
 
Table 2. MALDI TOF MS of Phosphorothioate Oligonucleotide-Peptide Conjugates 
 
Table 3. siRNA sequences targeting the hTERT gene
 
 
 
 
 
 
 
 
 
 
 
